Browsing Tag
Bridion
3 posts
Merck (NYSE: MRK) reports Q2 loss, hikes revenue view as Keytruda Qlex ramps
Merck raised 2026 sales guidance to $67.3B but cut EPS to $2.76 on Terns charge. Lipfendra approval and $463M Keytruda Qlex quarter reshape the 2028 cliff.
Zydus Lifesciences secures FDA nod for high-demand Sugammadex Injection
Zydus Lifesciences Limited, a formidable name in the pharmaceutical realm, proudly announces its final endorsement from the United…
Zydus Lifesciences gets tentative FDA approval for Sugammadex generic
Zydus Lifesciences (previously Cadila Healthcare) said that its American subsidiary Zydus Pharmaceuticals (USA) has secured tentative approval for…